ATAD5: A Potential Drug Target and Biomarker (G79915)

Target Name: ATAD5

NCBI ID: G79915

ATAD5

ATAD5: A Potential Drug Target and Biomarker

ATAD5 (chromosome fragility-associated gene 1 protein) is a gene that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The protein is found on chromosome 12 and is encoded by the ATAD5 gene.

Mutations in the ATAD5 gene have been linked to a number of genetic disorders, including Down syndrome, which is a chromosomal abnormality that is characterized by the presence of an extra chromosome 21 at one or more times in a cell. In addition, mutations in the ATAD5 gene have also been linked to a variety of other disorders, including Fragile X syndrome, a genetic disorder that is characterized by the presence of a Fragile X chromosome, and Palsy of Becker disease, a progressive muscle weakness and wasting disorder.

The protein encoded by the ATAD5 gene is a key regulator of the chromosome, and is involved in the maintenance of chromosomal stability. It plays a role in the regulation of microtubule dynamics and the dynamics of the nuclear envelope, which is the outer layer of the cell nucleus.

In addition to its role in chromosomal regulation, ATAD5 has also been shown to play a number of other roles in the cell. For example, it has been shown to be involved in the regulation of cell adhesion, and in the development and progression of cancer. In addition, ATAD5 has also been shown to play a role in the regulation of intracellular signaling pathways, including the PI3K/Akt signaling pathway.

Drug targeting

Given the diverse range of roles that ATAD5 has been shown to play in the cell, it is an attractive target for drug development. In addition to its potential use as a therapeutic drug, ATAD5 may also be used as a biomarker for a variety of diseases.

One potential approach to drug targeting ATAD5 is to use small molecules that can inhibit its activity. This could involve using drugs that specifically target the protein, or drugs that inhibit the activity of ATAD5 by interacting with it in a way that disrupts its function.

Another potential approach to drug targeting ATAD5 is to use antibodies that can selectively target the protein. This could involve using antibodies that are designed to recognize a specific epitope (a portion of the protein that is unique to one species) on the protein, and then using these antibodies to block the activity of ATAD5.

Biomarker potential

In addition to its potential use as a drug target, ATAD5 may also be used as a biomarker for a variety of diseases. For example, down syndrome is a genetic disorder that is characterized by the presence of an extra chromosome 21, and it is possible that ATAD5 could be used as a biomarker for this disorder.

In addition, ATAD5 may also be used as a biomarker for other disorders, such as Fragile X syndrome and Palsy of Becker disease. These disorders are characterized by the presence of specific genetic mutations, and it is possible that ATAD5 could be used as a biomarker for these disorders by detecting the presence of these mutations in the DNA of affected individuals.

Conclusion

ATAD5 is a gene that has been identified as a potential drug target or biomarker for a variety of diseases. Its role in chromosomal regulation and its involvement in the regulation of intracellular signaling pathways make it an attractive target for drug development. In addition to its potential use as a therapeutic drug, ATAD5 may also be used as a biomarker for a variety of disorders. Further research is needed to fully understand the role of ATAD5 in the development and progression of disease.

Protein Name: ATPase Family AAA Domain Containing 5

Functions: Has an imporant role in DNA replication and in maintaining genome integrity during replication stress (PubMed:15983387, PubMed:19755857). Involved in a RAD9A-related damage checkpoint, a pathway that is important in determining whether DNA damage is compatible with cell survival or whether it requires cell elimination by apoptosis (PubMed:15983387). Modulates the RAD9A interaction with BCL2 and thereby induces DNA damage-induced apoptosis (PubMed:15983387). Promotes PCNA deubiquitination by recruiting the ubiquitin-specific protease 1 (USP1) and WDR48 thereby down-regulating the error-prone damage bypass pathway (PubMed:20147293). As component of the ATAD5 RFC-like complex, regulates the function of the DNA polymerase processivity factor PCNA by unloading the ring-shaped PCNA homotrimer from DNA after replication during the S phase of the cell cycle (PubMed:23277426, PubMed:23937667). This seems to be dependent on its ATPase activity (PubMed:23277426). Plays important roles in restarting stalled replication forks under replication stress, by unloading the PCNA homotrimer from DNA and recruiting RAD51 possibly through an ATR-dependent manner (PubMed:31844045). Ultimately this enables replication fork regression, breakage, and eventual fork restart (PubMed:31844045). Both the PCNA unloading activity and the interaction with WDR48 are required to efficiently recruit RAD51 to stalled replication forks (PubMed:31844045). Promotes the generation of MUS81-mediated single-stranded DNA-associated breaks in response to replication stress, which is an alternative pathway to restart stalled/regressed replication forks (PubMed:31844045)

The "ATAD5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATAD5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets